AquaBounty Technologies, Inc. (NASDAQ:AQB) Short Interest Up 76.3% in January

AquaBounty Technologies, Inc. (NASDAQ:AQB) was the target of a significant growth in short interest in January. As of January 15th, there was short interest totaling 23,366 shares, a growth of 76.3% from the December 31st total of 13,256 shares. Based on an average trading volume of 28,413 shares, the short-interest ratio is currently 0.8 days. Currently, 0.6% of the shares of the stock are short sold. Currently, 0.6% of the shares of the stock are short sold. Based on an average trading volume of 28,413 shares, the short-interest ratio is currently 0.8 days.

AquaBounty Technologies Trading Down 5.2%

Shares of AQB stock opened at $0.91 on Friday. The stock has a market capitalization of $3.53 million, a price-to-earnings ratio of -1.10 and a beta of 1.24. AquaBounty Technologies has a 12-month low of $0.50 and a 12-month high of $2.95. The stock’s 50-day moving average price is $0.95 and its 200-day moving average price is $1.12.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of AquaBounty Technologies in a research report on Monday, December 22nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, AquaBounty Technologies has a consensus rating of “Sell”.

Institutional Trading of AquaBounty Technologies

A hedge fund recently bought a new stake in AquaBounty Technologies stock. Two Sigma Investments LP bought a new stake in shares of AquaBounty Technologies, Inc. (NASDAQ:AQB) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 37,565 shares of the company’s stock, valued at approximately $84,000. Two Sigma Investments LP owned approximately 0.97% of AquaBounty Technologies at the end of the most recent quarter. 8.92% of the stock is currently owned by institutional investors and hedge funds.

About AquaBounty Technologies

AquaBounty Technologies, Inc is a biotechnology company focused on aquaculture innovation through the development and commercialization of genetically engineered fish. Its flagship product, AquAdvantage Salmon, is an Atlantic salmon strain enhanced with a growth hormone gene that enables faster growth and more efficient feed conversion compared with conventional farmed salmon. By integrating biotechnology into seafood production, AquaBounty aims to address global protein demand while reducing the environmental footprint associated with marine aquaculture.

Founded in 1991, AquaBounty is headquartered in Maynard, Massachusetts, and operates a state-of-the-art, land-based incubation and grow-out facility in Panama.